EZ Traders Forum

[RIGATONI]

~SYBD News...


Synthetic Blood International to Present at Wall Street Analyst Forum on February 28; Letter to Shareholders Available at www.sybd.com
COSTA MESA, Calif., Feb 22, 2005 (BUSINESS WIRE) --
Synthetic Blood International, Inc. (OTCBB:SYBD) today announced that President and CEO Robert Nicora will present at The Wall Street Analyst Forum's 16th Annual Analyst Conference on Monday, February 28 at 9:00 a.m. EST. A live audio webcast including slides of the presentation will be available via the Presentations/Publications section of the Company's Web site at www.sybd.com . An archived presentation will be available for 30 days.

"We look forward to increasing investor awareness for our Company as we have recently begun enrolling patients in our first Phase II study with Oxycyte," said Mr. Nicora. "Oxycyte is our proprietary blood substitute and therapeutic oxygen carrier that we are developing for use in surgical and other medical situations. In this first Phase II study we will be measuring the safety and efficacy of Oxycyte administered to hip surgery patients to prevent diminished oxygen delivery to tissue."

The Wall Street Analyst Forum conference will be held at the Roosevelt Hotel in New York City. Analysts and institutional investors are invited to attend this presentation by contacting The Wall Street Analyst Forum at 802-253-7596 to register or request additional information.

The Company also announced that a Letter to Shareholders is now available on its Web site and can be accessed by visiting the "News Update" section of www.sybd.com and clicking "Letter to Shareholders."

About Synthetic Blood International

Synthetic Blood International is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development a blood substitute and a liquid ventilation product, and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for perfluorocarbons, and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including acute respiratory distress syndrome, stroke, myocardial infarction, surgery, trauma, malignant tumors and diabetes. For further information, visit www.sybd.com .

Safe Harbor Statement: The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking information made on the Company's behalf. All statements, other than statements of historical facts which address the Company's expectations of sources of capital or which express the Company's expectation for the future with respect to financial performance or operating strategies, can be identified as forward-looking statements. Such statements made by the Company are based on knowledge of the environment in which it operates, but because of the factors previously listed, as well as other factors beyond the control of the Company, actual results may differ materially from the expectations expressed in the forward-looking statements.

SOURCE: Synthetic Blood International, Inc.

Company Contact:
Synthetic Blood International Inc.
Joan Mahan, 800-809-6054

[e-mail]

or
Investor Contact:
Lippert/Heilshorn & Associates, Inc.
Jody Cain or Brandi Floberg, 310-691-7100

[e-mail]


[e-mail]


--------------------------------------------------------------------------------

Copyright (C) 2005 Business Wire. All rights reserved.

News provided by